Argentina Gastric Cancer Treatment Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 58.63 million |
 Market Size (Forecast Year) |
USD 92.37 million |
 CAGR |
% |
| Major Markets Players |
阿根廷胃癌治疗市场，按类型（腺癌、胃肠道间质瘤、类癌瘤、淋巴瘤等）、分期（第一期、第二期、第三期、第四期、其他）、治疗（化疗、靶向治疗、免疫检查点抑制剂、其他）、给药途径（肠外、口服、其他）、最终用户（医院、专科诊所、研究和学术机构、其他）、分销渠道（医院药房、零售药房、其他）划分 - 行业趋势和预测到 2030 年。
阿根廷胃癌治疗市场分析及规模
Data Bridge Market Research 分析称，阿根廷胃癌治疗市场在 2023 年为 5863 万美元，预计到 2031 年将达到 9237 万美元，预计在 2024 年至 2031 年的预测期内复合年增长率为 9.1%。由于胃癌治疗需求不断增长，“腺癌”在阿根廷胃癌治疗市场类型细分中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。
报告范围和市场细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
按类型（腺癌、胃肠道间质瘤、类癌瘤、淋巴瘤等）、分期（I 期、II 期、III 期、IV 期、其他）、治疗（化疗、靶向治疗、免疫检查点抑制剂、其他）、给药途径（肠外、口服、其他）、最终用户（医院、专科诊所、研究和学术机构、其他）、分销渠道（医院药房、零售药房、其他） |
|
涵盖的市场参与者 |
雅培（美国）、西门子医疗股份公司（德国）、Quidel Corporation（美国）、F. Hoffman-La Roche Ltd.（瑞士）、丹纳赫集团（美国）、Becton, Dickinson and Company（美国）、Chembio Diagnostics（美国）、EKF Diagnostics（英国）、Trinity Biotech plc（爱尔兰）、Instrumentation Laboratory（Werfen 公司）（美国）、Nova Biomedical（美国）、PTS Diagnostics（美国）、Sekisui Diagnostics（美国）、赛默飞世尔科技（美国）、bioMérieux SA（法国） |
|
市场机会 |
|
市场定义
胃癌是一种在胃壁中形成恶性（癌）细胞的疾病。年龄、饮食和胃病会影响患上胃癌的风险。胃癌的症状包括消化不良和胃部不适或疼痛。
阿根廷胃癌治疗市场动态
驱动程序
- 胃肠道肿瘤、淋巴瘤和腺癌发病率增加
随着癌症发病率的上升，日常生活活动受到限制，需要医疗护理。新一代测序 (NGS)、PCR 和 CLIA 技术有助于提供有效信息，以便正确诊断和预后癌症。胃肠道肿瘤、淋巴瘤和腺癌发病率的上升提高了利用最新技术进行早期检测和诊断的需求，从而推动了市场的增长。
- 酒精消费量增加，吸烟人数激增
流行病学、临床和实验室证据表明，吸烟和饮酒之间存在行为关系。吸烟和饮酒的结合除了单独吸烟带来的健康问题外，还会带来健康问题，因此这是一个严重的公共卫生问题，值得进一步研究。吸烟者每次吸入点燃的香烟都会发生化学连锁反应，产生数十种有害化学物质。香烟烟雾中的物质通过嘴唇、舌头和口腔吸入，进入喉咙，进入肺部，引起炎症并使这些身体部位暴露于致癌化学物质中。
酒精消费和吸烟的增加增加了对癌症诊断医疗设备的需求，从而推动了市场增长。
- 老年人口增加
随着全球老龄人口不断增长，关节炎、癌症、呼吸系统疾病、代谢性疾病、骨科、心血管等慢性疾病的患病率也不断上升。老年人更容易患病，因此年龄与需要诊断和治疗的疾病原因之间存在很强的相关性。
以下是与全球老年人口增加相关的一些统计数据：
随着年龄的增长和慢性病患病率的上升，对疾病早期诊断的需求也在增加。此外，随着人口的增长，医疗保健系统的压力也在增加，对预防和治疗老年慢性病的护理、服务和技术的需求也在增加。因此，全球医疗保健系统对用于诊断癌症的先进医疗设备的需求正在上升。
机会
- 自动化系统采用率上升
癌症是一种系统和网络疾病。这表明在癌细胞中，某些与网络相关的基因停止正常工作。在癌症治疗中应该解决这种基因网络中的复杂相互作用。人工智能（AI）算法的发展尤其迅速，这反映在肿瘤学的进步中。机器学习和神经网络在精准肿瘤学和系统医学中变得越来越重要。成像数据与临床和分子数据的结合开辟了一个充满可能性的世界。例如，放射基因组学是一个专注于多维数据处理的新领域。它也可以从人工智能的进步中受益。提高成像诊断的准确性是癌症诊断和治疗技术发展的一个主要问题，人工智能算法可以帮助自动化放射科医生和组织病理学家的工作，从而确保这一点。因此，自动化系统的广泛采用为该市场的增长提供了机会。
- 加大癌症诊断产品的研发力度
研发对于包括医疗保健行业在内的所有行业都至关重要。医疗保健行业开展广泛的研发不仅是为了创造收入，而且通常通过挽救或改善患者的生命来带来成果。药物开发或生物标志物开发需要从普通碱基中随机筛选活性成分，然后在动物模型中验证活性，以检查筛选程序，以在大量化合物中找到具有所需生物活性的少数化合物。药物研发使用不同的检测方法进行临床试验，例如细胞活力检测、细胞增殖检测、细胞毒性检测、细胞衰老检测和细胞死亡检测。制药和生物制药公司进行大量临床试验以成功完成药物或生物制剂、试剂和测试开发。如今，医疗保健公司越来越关注癌症诊断的研究和开发，这增加了对胃癌诊断的需求。此外，由于公共卫生支出和经济表现，全球研发活动正在不断增加。
限制/挑战
- 胃癌诊断检测费用高昂
胃癌诊断检测包括技术高度先进的产品。这些产品的开发需要开发商进行严格的研究和开发。因此，产品成本仍然很高，这相应地增加了检测成本。
- 批准辐射设备的复杂性的严格法规和政策
医疗器械监管在医疗保健领域发挥着重要作用。CT 扫描、PET 扫描和 MRI 等辐射设备对癌症诊断至关重要。但它们的批准和营销需要满足严格的监管标准并获得各监管机构的批准。这些严格的法规和批准辐射设备的复杂性的政策对市场增长构成了挑战。
这份阿根廷 胃癌治疗市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入来源、市场法规变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新等方面的机会。如需了解有关阿根廷 胃癌治疗市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
近期发展
- 2021 年 5 月，礼来公司宣布，美国食品药品监督管理局 (FDA) 已批准 CYRAMZA（雷莫芦单抗注射液，10 mg/mL 溶液）与厄洛替尼联合用于一线治疗表皮生长因子受体 (EGFR) 外显子 19 缺失或外显子 21 (L858R) 突变的转移性非小细胞肺癌 (NSCLC) 患者。凭借此项批准，CYRAMZA 现已获得六项 FDA 批准，用于治疗某些类型的肺癌、肝癌、胃癌和结直肠癌。该公司的这项新药批准增加了其在市场上的销量和需求，从而导致未来销量增加
阿根廷胃癌治疗市场范围
阿根廷 胃癌治疗市场根据类型、阶段、治疗、给药途径、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
类型
- 腺癌
- 淋巴瘤
- 胃肠道间质瘤
- 类癌瘤
- 其他的
阶段
- 第一阶段
- 第二阶段
- 第三阶段
- 第四阶段
治疗
- 化疗
- 靶向治疗
- 免疫疗法
- 其他的
给药途径
- 口服
- 肠外
最终用户
- 专科诊所
- 医院
- 研究与学术
- 研究所
- 其他的
分销渠道
- 零售药店
- 医院药房
- 其他的
竞争格局和阿根廷胃癌治疗市场份额分析
阿根廷 胃癌治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对阿根廷 胃癌治疗市场的关注有关。
阿根廷胃癌治疗市场的一些主要参与者包括：
- 雅培实验室（美国）
- 西门子医疗股份公司（德国）
- Quidel Corporation（美国）
- F. Hoffman-La Roche Ltd.（瑞士）
- 丹纳赫集团（美国）
- 碧迪公司 (美国)
- Chembio Diagnostics（美国）
- EKF 诊断（英国）
- Trinity Biotech plc（爱尔兰）
- 仪器实验室（Werfen 公司）（美国）
- Nova Biomedical（美国）
- PTS Diagnostics（美国）
- Sekisui Diagnostics（美国）
- 赛默飞世尔科技（美国）
- 生物梅里埃公司（法国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ARGENTINA GASTRIC CANCER TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE\
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 MARKET LIFELINE CURVE
2.7 DBMR MARKET POSITION GRID
2.8 VENDOR SHARE ANALYSIS
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 EPIDEMIOLOGY
6 REGULATIONS OF ARGENTINA GASTRIC CANCER TREATMENT MARKET
7 PIPELINE ANALYSIS FOR ARGENTINA GASTRIC CANCER TREATMENT
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA
8.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING
8.1.3 HIGH INCIDENCE OF OBESITY
8.1.4 RECENT ADVANCEMENT IN GASTRIC CANCER TREATMENT
8.2 RESTRAINTS
8.2.1 HIGH COST OF TESTING AND MEDICATIONS
8.2.2 ADVERSE SIDE-EFFECTS OF GASTRIC CANCER TREATMENT
8.3 OPPORTUNITIES
8.3.1 INCREASING DRUG APPROVALS
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.4 CHALLENGES
8.4.1 OLD AGE CHALLENGES
8.4.2 ALTERNATIVE GASTRIC CANCER THERAPIES
9 IMPACT OF COVID-19 PANDEMIC ON THE ARGENTINA GASTRIC CANCER TREATMENT MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY TYPE
10.1 OVERVIEW
10.2 ADENOCARCINOMA
10.3 GASTROINTESTINAL STROMAL TUMOR
10.4 CARCINOID TUMOR
10.5 LYMPHOMA
10.6 OTHERS
11 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY STAGES
11.1 OVERVIEW
11.2 STAGE III
11.3 STAGE II
11.4 STAGE IV
11.5 STAGE I
11.6 OTHERS
12 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT
12.1 OVERVIEW
12.2 CHEMOTHERAPY
12.2.1 OXALIPLATIN
12.2.2 CISPLATIN
12.2.3 FLUOROURACIL
12.2.4 DOCETAXEL
12.2.5 CAPECITABINE
12.2.6 CARBOPLATIN
12.2.7 EPIRUBICIN
12.2.8 PACLITAXEL
12.2.9 IRINOTECAN
12.2.10 OTHERS
12.3 TARGETED THERAPY
12.3.1 MONOCLONAL ANTIBODY THERAPY
12.3.1.1 TRASTUZUMAB (HERCEPTIN)
12.3.1.2 RAMUCIRUMAB
12.3.2 MULTIKINASE INHIBITORS
12.3.2.1 SUNITINIB
12.3.2.2 REGORAFENIB
12.4 IMMUNE CHECKPOINT INHIBITORS
12.5 OTHERS
13 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 PARENTERAL
13.2.1 INTRAVENOUS
13.2.2 SUBCUTANEOUS
13.2.3 OTHERS
13.3 ORAL
13.3.1 TABLET
13.3.2 CAPSULE
13.3.3 OTHERS
13.4 OTHERS
14 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALITY CLINICS
14.4 RESEARCH & ACADEMIC INSTITUTES
14.5 OTHERS
15 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 OTHERS
16 ARGENTINA GASTRIC CANCER TREATMENT MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ARGENTINA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 MERCK & CO., INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENTS
18.2 ASTRAZENECA
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 PRODUCT PORTFOLIO
18.2.4 RECENT DEVELOPMENTS
18.3 PFIZER INC.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENT
18.4 ELI LILLY AND COMPANY
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENT
18.5 NOVARTIS AG
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 TEVA PHARMACEUTICAL INDUSTRIES LTD
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.6.4.1 EXPANSION:
18.7 GENENTECH, INC. (A SUBSIDIARY OF A SUBSIDIARY OF F. HOFFMANN-LA ROCHE)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 LABORATORIO VARIFARMA SA
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.8.3.1 EXPANSION:
18.9 TUTEUR
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 CELNOVA PHARMA
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.10.3.1 PARTNERSHIP:
18.11 ERIOCHEM SA
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 GRUPO BIOTOSCANA
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENT
18.13 LABORATORIOS IMA
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENTS
18.14 BRISTOL-MYERS SQUIBB COMPANY
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.15 SANOFI
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
表格列表
TABLE 1 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 2 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY STAGES , 2019-2028 (USD MILLION)
TABLE 3 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT , 2019-2028 (USD MILLION)
TABLE 4 ARGENTINA CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 5 ARGENTINA TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 6 ARGENTINA MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 7 ARGENTINA MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 8 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 9 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2028 (USD MILLION)
TABLE 10 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 11 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 12 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
图片列表
FIGURE 1 ARGENTINA GASTRIC CANCER TREATMENT MARKET: SEGMENTATION
FIGURE 2 ARGENTINA GASTRIC CANCER TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ARGENTINA GASTRIC CANCER TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ARGENTINA GASTRIC CANCER TREATMENT MARKET: COUNTRY VS REGIONAL MARKET ANALYSIS
FIGURE 5 ARGENTINA GASTRIC CANCER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ARGENTINA GASTRIC CANCER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ARGENTINA GASTRIC CANCER TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ARGENTINA GASTRIC CANCER TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 ARGENTINA GASTRIC CANCER TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 ARGENTINA GASTRIC CANCER TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASED HEALTHCARE SPENDING AND THE RISE IN THE PREVALENCE OF TYPES OF GASTRIC CANCER ARE EXPECTED TO DRIVE THE ARGENTINA GASTRIC CANCER TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 ADENOCARCINOMA MARKET IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ARGENTINA GASTRIC CANCER TREATMENT MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ARGENTINA GASTRIC CANCER TREATMENT MARKET
FIGURE 14 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2020
FIGURE 15 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2021-2028 (USD MILLION)
FIGURE 16 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 17 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY STAGES, 2020
FIGURE 19 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY STAGES, 2021-2028 (USD MILLION)
FIGURE 20 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY STAGES, CAGR (2021-2028)
FIGURE 21 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 22 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, 2020
FIGURE 23 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, 2021-2028 (USD MILLION)
FIGURE 24 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, CAGR (2021-2028)
FIGURE 25 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 26 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 27 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
FIGURE 28 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 29 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY END USER 2020
FIGURE 31 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 32 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY END USER, CAGR (2021-2028)
FIGURE 33 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 35 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 36 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 37 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 ARGENTINA GASTRIC CANCER TREATMENT MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
